Hybridization of ALK break probe to a lung adenocarcinoma tissue section showing positive translocation signal (1RG1R1G).

RUO - ALK Break

Translocations of the ALK (anaplastic lymphoma kinase) gene at 2p23 have originally been associated with anaplastic lymphomas, B-cell lymphomas, neuroblastomas and myofibroblastic tumors. At least 21 translocation partners have been described, however 80% of the translocations involves the NPM1 gene (5q35). ALK rearrangements have been described in non-small cell lung cancer (NSCLC) cases. Multiple tyrosine kinsae inhibitors (TKI's) specific for ALK have since been approved for first line treatment of NSCLC-patients carrying the fusion gene ALK-EML4. These ALK inhibitors include crizotinib (Xalkori), alectinib (Alecensa) and ceritinib (Zykadia). The ALK (2p23) Break probe is optimized to detect translocations involving the ALK gene region at 2p23.

References:
Soda et al, Nature, 2007, 448, 561-566.
Kwak et al, J Clin Oncol., 27(26):4247-53.
Koivunen et al, Clin Cancer Res, 2008, 14, 4275-4283.
Log in or add to cart
to view the price of this item.
ou DEMANDEZ un devis groupé.

Produits

Produits

KI-10747
ALK (2p23) Break
Stock limité (Plus de détails))
Ships via Overnight
Log in or add to cart
to view the price of this item.
ou DEMANDEZ un devis groupé.

Téléchargements

Téléchargements

Recently Viewed